Last reviewed · How we verify
Actomol (MEBANAZINE)
At a glance
| Generic name | MEBANAZINE |
|---|---|
| Drug class | Monoamine Oxidase Inhibitors |
| Target | Amine oxidase [flavin-containing] A |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Depressive disorder
Common side effects
Drug interactions
- Alpha/Beta Agonists
- Amphetamines
- Indirectly Acting Sympathomimetic Amines
- Selective Serotonin Reuptake Inhibitors
- Serotonin/Norepinephrine Reuptake Inhibitors
- Tricyclic Antidepressants
- buspirone
- dextromethorphan
- levodopa
- methyldopa
- mirtazapine
- pethidine
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Actomol CI brief — competitive landscape report
- Actomol updates RSS · CI watch RSS